Hepion Pharmaceuticals Inc (HEPA) - Total Assets
Based on the latest financial reports, Hepion Pharmaceuticals Inc (HEPA) holds total assets worth $3.07 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Hepion Pharmaceuticals Inc net assets for net asset value and shareholders' equity analysis.
Hepion Pharmaceuticals Inc - Total Assets Trend (2012–2025)
This chart illustrates how Hepion Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data.
Hepion Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Hepion Pharmaceuticals Inc's total assets of $3.07 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 59.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Hepion Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Hepion Pharmaceuticals Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hepion Pharmaceuticals Inc's current assets represent 100.0% of total assets in 2025, unchanged from 100.0% in 2012.
- Cash Position: Cash and equivalents constituted 59.6% of total assets in 2025, down from 100.0% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Hepion Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Hepion Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Hepion Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.25 | 0.51 | 41.06 |
| Quick Ratio | 10.25 | 0.51 | 41.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.77 Million | $-1.53 Million | $114.88 Million |
Hepion Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Hepion Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.66 |
| Latest Market Cap to Assets Ratio | 0.20 |
| Asset Growth Rate (YoY) | 90.2% |
| Total Assets | $3.07 Million |
| Market Capitalization | $604.26K USD |
Valuation Analysis
Below Book Valuation: The market values Hepion Pharmaceuticals Inc's assets below their book value (0.20x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Hepion Pharmaceuticals Inc's assets grew by 90.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Hepion Pharmaceuticals Inc (2012–2025)
The table below shows the annual total assets of Hepion Pharmaceuticals Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $3.07 Million | +90.24% |
| 2024-12-31 | $1.61 Million | -91.08% |
| 2023-12-31 | $18.09 Million | -69.97% |
| 2022-12-31 | $60.24 Million | -41.82% |
| 2021-12-31 | $103.55 Million | +112.87% |
| 2020-12-31 | $48.65 Million | +136.01% |
| 2019-12-31 | $20.61 Million | +151.69% |
| 2018-12-31 | $8.19 Million | -27.23% |
| 2017-12-31 | $11.25 Million | -14.14% |
| 2016-12-31 | $13.11 Million | +143.75% |
| 2015-12-31 | $5.38 Million | +168.74% |
| 2014-12-31 | $2.00 Million | 0.00% |
| 2013-12-31 | $2.00 Million | +2207.42% |
| 2012-12-31 | $86.72K | -- |
About Hepion Pharmaceuticals Inc
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as … Read more